| Followers | 187 |
| Posts | 15512 |
| Boards Moderated | 0 |
| Alias Born | 08/26/2010 |
Tuesday, July 18, 2023 10:10:32 AM
.22 settle
Recent PVLA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:05:12 PM
- Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards • GlobeNewswire Inc. • 05/21/2026 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 09:47:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:35:15 PM
- Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malforma • GlobeNewswire Inc. • 05/20/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 11:30:16 AM
- Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology • GlobeNewswire Inc. • 05/15/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 11:30:15 AM
- Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market • GlobeNewswire Inc. • 05/13/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 01:09:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 12:30:32 PM
- Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas • GlobeNewswire Inc. • 05/04/2026 11:30:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:14:31 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 08:11:39 PM
- Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 • GlobeNewswire Inc. • 04/30/2026 11:30:00 AM
- Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 • GlobeNewswire Inc. • 04/20/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:05:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/15/2026 08:05:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/15/2026 08:05:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 11:30:08 AM
- Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors • GlobeNewswire Inc. • 04/13/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 11:30:15 AM
- Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
